Syndax Pharmaceuticals Inc (SNDX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q4 '19: 1.5M Q1 '20: 1.5M Q2 '20: 1.5M Q3 '20: 1.5M Q4 '20: 1.5M Q1 '21: 1.5M Q2 '21: 1.5M Q3 '21: 13.5M Q4 '21: 139.7M Q4 '23: 0 Q1 '24: 0 Q2 '24: 3.5M Q3 '24: 16M Q4 '24: 23.7M Q1 '25: 43.7M Q2 '25: 78.2M Q3 '25: 111.6M Q4 '25: 172.6M Q1 '26: 217.4M Q2 '26: 252.3M Q1 '20 Q4 '20 Q3 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '20: -65.8M Q4 '20: -71.4M Q1 '21: -83.5M Q2 '21: -89.2M Q3 '21: -89.4M Q4 '22: -151.8M Q1 '23: -160.9M Q2 '23: -172.9M Q3 '23: -194.1M Q4 '23: -230M Q1 '24: -263.5M Q2 '24: -288M Q3 '24: -321.2M Q4 '24: -339.7M Q1 '25: -343.9M Q2 '25: -339.1M Q3 '25: -306.9M Q4 '25: -273.1M Q1 '26: -223.5M Q2 '26: -194.2M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '20: -66.7M Q4 '20: -73.2M Q1 '21: -85.6M Q2 '21: -91.5M Q3 '21: -91.7M Q4 '22: -149.3M Q1 '23: -153.3M Q2 '23: -160.3M Q3 '23: -176.1M Q4 '23: -209.4M Q1 '24: -240.6M Q2 '24: -264.1M Q3 '24: -297.1M Q4 '24: -318.8M Q1 '25: -331.2M Q2 '25: -335M Q3 '25: -311.6M Q4 '25: -285.4M Q1 '26: -243.2M Q2 '26: -220.8M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '20: -68.4M Q4 '20: -71.3M Q1 '21: -77.9M Q2 '21: -80.6M Q3 '21: -87.2M Q4 '22: -133.7M Q1 '23: -131M Q2 '23: -126M Q3 '23: -142.1M Q4 '23: -160.6M Q1 '24: -204.9M Q2 '24: -241.2M Q3 '24: -258.9M Q4 '24: -274.9M Q1 '25: -286.5M Q2 '25: -302.7M Q3 '25: -310.9M Q4 '25: -323M Q1 '26: -278.2M Q2 '26: -220.6M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '16: -23M Q3 '16: -29.3M Q4 '16: -35.4M Q3 '18: -66.4M Q4 '18: -68.7M Q2 '16 Q3 '16 Q4 '16 Q3 '18 Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '21: 51.6M Q3 '21: 52M Q1 '22: 59M Q2 '22: 60.2M Q3 '22: 60.7M Q1 '23: 69.4M Q2 '23: 69.6M Q3 '23: 69.9M Q1 '24: 85.2M Q2 '24: 85.3M Q3 '24: 85.4M Q1 '25: 86.2M Q2 '25: 86.3M Q3 '25: 86.6M Q1 '26: 88.3M Q2 '26: 89M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: -1.88 Q4 '20: -1.88 Q1 '21: -1.86 Q2 '21: -1.88 Q3 '21: -1.82 Q4 '22: -2.45 Q1 '23: -2.41 Q2 '23: -2.43 Q3 '23: -2.58 Q4 '23: -2.97 Q1 '24: -3.23 Q2 '24: -3.39 Q3 '24: -3.64 Q4 '24: -3.72 Q1 '25: -3.85 Q2 '25: -3.88 Q3 '25: -3.60 Q4 '25: -3.29 Q1 '26: -2.79 Q2 '26: -2.51 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.